Background: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). The only report of Serum Sickness (SS) in a MS patient occurred during treatment with natalizumab. Non-protein drugs, such as some antibiotics, may induce “SS-like” reactions (SSLR), whose clinical and laboratory features may partially overlap with the traditional SS. Objective: To report a case of SS/SSLR in a RRMS patient treated with alemtuzumab. Case report: A 42-year-old-woman with RRMS developed SS/SSLR in the first week after the first alemtuzumab treatment. Concomitant medications included trimethoprim-sulfamethoxazole at low dose. Intravenous methylprednisolone therapy led to clinical resolution and normalization of serum inflammatory markers. Conclusion: SS/SSLR should be considered in patients treated with alemtuzumab developing delayed fever, rash and arthralgia and differentiated with Infusion Associated Reactions (IARs) and infections.

Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report

Lapucci C;Mikulska M;Palmeri S;Mancardi G;Uccelli A;Laroni A.
2018

Abstract

Background: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). The only report of Serum Sickness (SS) in a MS patient occurred during treatment with natalizumab. Non-protein drugs, such as some antibiotics, may induce “SS-like” reactions (SSLR), whose clinical and laboratory features may partially overlap with the traditional SS. Objective: To report a case of SS/SSLR in a RRMS patient treated with alemtuzumab. Case report: A 42-year-old-woman with RRMS developed SS/SSLR in the first week after the first alemtuzumab treatment. Concomitant medications included trimethoprim-sulfamethoxazole at low dose. Intravenous methylprednisolone therapy led to clinical resolution and normalization of serum inflammatory markers. Conclusion: SS/SSLR should be considered in patients treated with alemtuzumab developing delayed fever, rash and arthralgia and differentiated with Infusion Associated Reactions (IARs) and infections.
File in questo prodotto:
File Dimensione Formato  
Lapucci SSLR.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 356.31 kB
Formato Adobe PDF
356.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11567/927743
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact